Research Exclusivity Sample Clauses

The Research Exclusivity clause grants one party the exclusive right to conduct research activities within a specified field or on certain intellectual property. In practice, this means that the party receiving exclusivity is the only one permitted to perform research, develop, or test products related to the defined subject matter, often for a set period and sometimes within a particular geographic area. This clause is essential for protecting the investment and competitive advantage of the exclusive party, ensuring that no other parties can exploit the same research opportunities during the exclusivity term.
POPULAR SAMPLE Copied 4 times
Research Exclusivity. During the Research Term, DIVERSA will not collaborate with or license the rights to any Third Party to use any Licensed Enzyme in the Approved Fields, so long as the LLC satisfies the diligence obligations set forth in the Work Plan with respect to the development of the applicable Licensed Enzyme. During the Research Term, the LLC will not collaborate with or license the rights to any Third Party to discover or evolve any enzyme in the Approved Fields.
View Source
Research Exclusivity. During the Research Term, DIVERSA will not collaborate with or license the rights to any Third Party to use any [*****] Enzyme in a Research [*****] to convert a Research [*****] to a [*****], as defined in Appendix [*****], so long as DOW satisfies the diligence obligations set forth in the [*****] Plan with respect to the development of the applicable [*****] Enzyme. During the Research Term, DOW will not collaborate with or license the rights to any Third Party to evolve any enzyme in a Research [*****] to convert a Research [*****] to a [*****], as defined in Appendix [*****].
View SourceView Similar (3)
Research Exclusivity. A. During the Research Term, MAXYGEN will not collaborate with any entity nor undertake any research activities not for the direct benefit of PIONEER with the intent of using Shuffling Technology to [*******] ("the Exclusive Trait Areas"). B. During the Research Term, MAXYGEN will conduct non-exclusive research in connection with the R&D Program in the following Trait Categories: [*******]. C. It is understood and agreed that, subject to its obligation to conduct research pursuant to (P)2.6B, MAXYGEN may conduct research on its own behalf and with third parties with respect to any gene and/or Plant, except with regard to the Exclusive Trait Areas for which PIONEER retains exclusivity, including without limitation, research with respect to the Trait Categories and PIONEER Crops subject to (P)2.6B. -39-
View SourceView Similar (3)
Research Exclusivity. ProdiGene agrees that it will not perform research and/or development or enter into any commercial agreement in or related to an Elected Research Program with any third party during the term of such Elected Research Program, after which ProdiGene, subject to its obligations of confidentiality, exclusivity and to proprietary rights granted to GCI hereunder, may continue such research without regard to GCI.
View SourceView Similar (2)
Research Exclusivity. 2.7.1 Exclusive and Co-Exclusive Trait Categories. During the ------------------------------------------- Research Term, Maxygen (i) will conduct research exclusively with Zeneca in the Trait Categories of [*******] and (ii) may only conduct research with Zeneca and up to [*******] other [*******] in the Trait Categories of [*******].
View SourceView Similar (2)
Research Exclusivity. After the Effective Date and until two (2) years after the end of the Research Term, subject to Sequana's existing agreements with third parties relating to asthma patient samples and such further agreements as the JRC may approve, neither Party will conduct any research in the Field with any other third party except as provided according to Article 6.2; provided, however, BI may collaborate with research and development relating to Asthma with third parties, outside the Field. Notwithstanding the above, either party may conduct research and commercialization activities with respect to diseases other than Asthma, alone or with third parties. Notwithstanding Article 6.1.1, in the event that Sequana materially breaches the Agreement, and BI terminates this Agreement pursuant to Section 12.2, BI may enter into collaborations with third parties to conduct research in the Field.
View Source
Research Exclusivity. During the Research Term, the Parties agree to cooperate exclusively with each other in carrying out research and development relating to uPA Inhibitors. Neither Party shall, during the Research Term, carry out any research in the Field relating to the discovery of uPA Inhibitors except pursuant to this Agreement unless the Parties mutually agree otherwise in writing. Neither Party shall enter into any agreement with a Third Party which would prevent it from performing its obligations under this Agreement.
View SourceView Similar (2)
Research Exclusivity. During the Term and continuing thereafter for a period of *** (***) ***, Pharmacopeia agrees that it will not ***.
View Source
Research Exclusivity 
View SourceView Similar (2)

Related to Research Exclusivity

  • Exclusivity Without prejudice to the Company’s rights under Section 5.4, the Company agrees not to appoint any other depositary for issuance of depositary shares, depositary receipts or any similar securities or instruments so long as The Bank of New York Mellon is acting as Depositary under this Deposit Agreement.

  • Research Use The Requester agrees that if access is approved, (1) the PI named in the DAR and (2) those named in the “Senior/Key Person Profile” section of the DAR, including the Information Technology Director and any trainee, employee, or contractor1 working on the proposed research project under the direct oversight of these individuals, shall become Approved Users of the requested dataset(s). Research use will occur solely in connection with the approved research project described in the DAR, which includes a 1-2 paragraph description of the proposed research (i.e., a Research Use Statement). Investigators interested in using Cloud Computing for data storage and analysis must request permission to use Cloud Computing in the DAR and identify the Cloud Service Provider (CSP) or providers and/or Private Cloud System (PCS) that they propose to use. They must also submit a Cloud Computing Use Statement as part of the DAR that describes the type of service and how it will be used to carry out the proposed research as described in the Research Use Statement. If the Approved Users plan to collaborate with investigators outside the Requester, the investigators at each external site must submit an independent DAR using the same project title and Research Use Statement, and if using the cloud, Cloud Computing Use Statement. New uses of these data outside those described in the DAR will require submission of a new DAR; modifications to the research project will require submission of an amendment to this application (e.g., adding or deleting Requester Collaborators from the Requester, adding datasets to an approved project). Access to the requested dataset(s) is granted for a period of one (1) year, with the option to renew access or close-out a project at the end of that year. Submitting Investigator(s), or their collaborators, who provided the data or samples used to generate controlled-access datasets subject to the NIH GDS Policy and who have Institutional Review Board (IRB) approval and who meet any other study specific terms of access, are exempt from the limitation on the scope of the research use as defined in the DAR.

  • Commercialization License Subject to the terms of this Agreement, including without limitation Section 2.2 and Theravance's Co-Promotion rights in Section 5.3.2, Theravance hereby grants to GSK, and GSK accepts, an exclusive license under the Theravance Patents and Theravance Know-How to make, have made, use, sell, offer for sale and import Alliance Products in the Territory.

  • Research License Each Collaborator shall allow the other Collaborator to practice any of its Non- Subject Inventions for the purpose of performing the Cooperative Work. No license, express or implied, for commercial application(s) is granted to either Collaborator in Non-Subject Inventions by performing the Cooperative Work. For commercial application(s) of Non-Subject Inventions, a license must be obtained from the owner.

  • For clarity the time allowances provided in clause 2.10 shall operate to reduce the maximum timetabled classroom teaching time specified in clause 4.2 of this agreement.